China Shineway Pharmaceutical Group Limited (C1S) - Total Assets
Based on the latest financial reports, China Shineway Pharmaceutical Group Limited (C1S) holds total assets worth €10.78 Billion EUR (≈ $12.60 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check how aggressively does China Shineway Pharmaceutical Group Limi reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
China Shineway Pharmaceutical Group Limited - Total Assets Trend (2013–2025)
This chart illustrates how China Shineway Pharmaceutical Group Limited's total assets have evolved over time, based on quarterly financial data. Check cash flow quality index of China Shineway Pharmaceutical Group Limi to evaluate the quality of earnings relative to operating cash generation.
China Shineway Pharmaceutical Group Limited - Asset Composition Analysis
Current Asset Composition (December 2025)
China Shineway Pharmaceutical Group Limited's total assets of €10.78 Billion consist of 86.3% current assets and 13.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 66.7% |
| Accounts Receivable | €805.93 Million | 7.5% |
| Inventory | €691.30 Million | 6.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €15.72 Million | 0.2% |
| Goodwill | €165.96 Million | 1.5% |
Asset Composition Trend (2013–2025)
This chart illustrates how China Shineway Pharmaceutical Group Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see China Shineway Pharmaceutical Group Limi (C1S) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Shineway Pharmaceutical Group Limited's current assets represent 86.3% of total assets in 2025, an increase from 67.6% in 2013.
- Cash Position: Cash and equivalents constituted 66.7% of total assets in 2025, up from 39.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, unchanged from 1.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 7.5% of total assets.
China Shineway Pharmaceutical Group Limited Competitors by Total Assets
Key competitors of China Shineway Pharmaceutical Group Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
SIMCERE PHARMAC. GRP LTD
F:S2P
|
Germany | €14.73 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥11.13 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
China Shineway Pharmaceutical Group Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.71 | 3.51 | 4.62 |
| Quick Ratio | 3.43 | 3.18 | 4.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €6.79 Billion | €6.15 Billion | €4.32 Billion |
China Shineway Pharmaceutical Group Limited - Advanced Valuation Insights
This section examines the relationship between China Shineway Pharmaceutical Group Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.74 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 7.3% |
| Total Assets | €10.78 Billion |
| Market Capitalization | $724.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values China Shineway Pharmaceutical Group Limited's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: China Shineway Pharmaceutical Group Limited's assets grew by 7.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below shows the annual total assets of China Shineway Pharmaceutical Group Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €10.78 Billion ≈ $12.60 Billion |
+7.33% |
| 2024-12-31 | €10.04 Billion ≈ $11.74 Billion |
+4.88% |
| 2023-12-31 | €9.57 Billion ≈ $11.19 Billion |
+16.30% |
| 2022-12-31 | €8.23 Billion ≈ $9.62 Billion |
+14.27% |
| 2021-12-31 | €7.20 Billion ≈ $8.42 Billion |
-0.13% |
| 2020-12-31 | €7.21 Billion ≈ $8.43 Billion |
+1.15% |
| 2019-12-31 | €7.13 Billion ≈ $8.34 Billion |
+5.94% |
| 2018-12-31 | €6.73 Billion ≈ $7.87 Billion |
+1.00% |
| 2017-12-31 | €6.67 Billion ≈ $7.79 Billion |
+3.09% |
| 2016-12-31 | €6.47 Billion ≈ $7.56 Billion |
+5.07% |
| 2015-12-31 | €6.15 Billion ≈ $7.19 Billion |
+4.16% |
| 2014-12-31 | €5.91 Billion ≈ $6.91 Billion |
+2.95% |
| 2013-12-31 | €5.74 Billion ≈ $6.71 Billion |
-- |
About China Shineway Pharmaceutical Group Limited
China Shineway Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and trade of Chinese pharmaceutical products in the People's Republic of China and Hong Kong. The company offers Chinese medicines in the form of injection, soft capsules, and granules; tablets, pills, oral liquid, and powder; and traditional Chinese medicine granules … Read more